COLL — Collegium Pharmaceutical Cashflow Statement
0.000.00%
Last trade - 00:00- $860.81m
- $1.55bn
- $631.45m
- 64
- 82
- 76
- 87
Annual cashflow statement for Collegium Pharmaceutical, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 26.8 | 71.5 | -25 | 48.2 | 69.2 |
| Depreciation | |||||
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 30.9 | 27.7 | 36.2 | 57.8 | 44.7 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -25.3 | 13.5 | -12.7 | 21.7 | -51.3 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | 93.9 | 104 | 124 | 275 | 205 |
| Capital Expenditures | -374 | -1.94 | -574 | -0.461 | -1.65 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | — | — | — | -70.4 | -286 |
| Acquisition of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -374 | -1.94 | -574 | -70.8 | -288 |
| Financing Cash Flow Items | -2.25 | -4.15 | -4.04 | -8.36 | -19.2 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 286 | -89.3 | 437 | -140 | -60.6 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 6.64 | 12.3 | -12.7 | 63.8 | -143 |